uploads///Chart  Oncology

Examining Bristol-Myers Squibb’s Oncology Portfolio’s 2Q17

By

Jul. 31 2017, Published 2:38 p.m. ET

Oncology portfolio

The key products in Bristol-Myers Squibb’s (BMY) oncology portfolio include Empliciti, Opdivo, Sprycel, and Yervoy. Let’s take a closer look at these drugs and their performances.

The above graph shows the revenues for BMY’s oncology drugs over the last few quarters.

Article continues below advertisement

Empliciti

Empliciti, a new oncology drug, was launched in the US markets in December 2015 and in the European markets in May 2016. The drug reported revenue of $55 million in 2Q17, a 62% rise compared to $34 million in 2Q16. The drug reported revenue of $37 million from US sales in 2Q17, a rise of 12% compared to 2Q16.

Opdivo

Opdivo is a human PD-1 blocking antibody used for the treatment of lung cancer and melanoma. Opdivo is part of BMY’s alliance with Ono Pharmaceutical. Opdivo reported a ~42% rise in revenue to $1.2 billion in 2Q17, compared to $840 million in 2Q16. The drug reported revenue of $768 million from US sales in 2Q17, a 19% rise compared to 2Q16.

Article continues below advertisement

Sprycel

Sprycel, an oral inhibitor, reported a rise of 12% in its 2Q17 revenue to $506 million, compared to $451 million in 2Q16, following increased demand for the drug in US markets. The drug reported revenue of $281 million from US sales during 2Q17, a 21% rise compared to 2Q16.

Yervoy

Yervoy, a monoclonal antibody used to treat melanoma, reported a 34% rise in its 2Q17 revenue to $322 million, compared to $241 million in 2Q16. Yervoy’s revenue saw a 37% rise in US markets, offset by a fall in international revenue due to competition. Yervoy competes with Merck & Co.’s (MRK) Keytruda.

To divest company-specific risks, investors can consider ETFs such as the PowerShares Dynamic Pharmaceuticals ETF (PJP), which holds 4.7% of its total assets in Bristol-Myers Squibb. PJP also holds 5.3% in Celgene (CELG), 4.7% in Pfizer (PFE), and 4.5% in Merck & Co.

Advertisement

More From Market Realist

  • CONNECT with Market Realist
  • Link to Facebook
  • Link to Twitter
  • Link to Instagram
  • Link to Email Subscribe
Market Realist Logo
Do Not Sell My Personal Information

© Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.